China Biotech Services Holdings (8037) Fundamentals 2026 — Revenue Analysis | SniperIQ
China Biotech Services Holdings (8037) is a HK-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of HK$634M, trading at HK$0.65 on the HKSE. This SniperIQ fundamentals page covers China Biotech Services Holdings's valuation, profitability (net margin -93.6%), revenue (HK$74M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is China Biotech Services Holdings's market cap?
China Biotech Services Holdings (8037) has a market capitalization of approximately HK$634M, trading at HK$0.65 on the HKSE. Market cap moves with the live share price.
What is China Biotech Services Holdings's P/E ratio?
China Biotech Services Holdings's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is China Biotech Services Holdings?
China Biotech Services Holdings runs a net profit margin of -93.6%, a gross margin of 10.5%, and an operating margin of -103.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does China Biotech Services Holdings generate?
China Biotech Services Holdings reported revenue of HK$74M for fiscal year 2025, with net income of -HK$69M and earnings per share (EPS) of -0.0705. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does China Biotech Services Holdings pay a dividend?
China Biotech Services Holdings does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is China Biotech Services Holdings financially healthy?
China Biotech Services Holdings carries a debt-to-equity ratio of 2.06x and a current ratio of 0.23x, with a market beta of -0.71. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is China Biotech Services Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For China Biotech Services Holdings (8037) the key facts are: market cap HK$634M, revenue HK$74M, 52-week range 0.3-1.33. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track China Biotech Services Holdings's full fundamentals live
Get China Biotech Services Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.